MYOK - MyoKardia, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
55.40
-0.45 (-0.81%)
As of 11:34AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close55.85
Open55.65
Bid55.50 x 1800
Ask55.55 x 1000
Day's range55.15 - 55.65
52-week range13.35 - 62.83
Volume29,414
Avg. volume413,414
Market cap2.198B
Beta3.46
PE ratio (TTM)N/A
EPS (TTM)-1.44
Earnings date6 Aug 2018 - 10 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est71.33
Trade prices are not sourced from all markets
  • GlobeNewswire23 days ago

    MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase 3 EXPLORER-HCM clinical trial.  The pivotal study is intended to evaluate the efficacy and safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).  MyoKardia expects to report data from the Phase 3 trial in the second half of 2020. EXPLORER-HCM is a multi-national randomized double-blind study that will enroll approximately 220 patients with symptomatic oHCM.  Patients will be randomized on a 1:1 basis to receive either mavacamten or placebo for a 30-week treatment period.  The EXPLORER-HCM trial design incorporates individualized dosing, including two dose adjustments during the 30-week treatment period based on measurements of provoked left ventricular outflow tract (LVOT) gradient.  All assessments and dose adjustments will be conducted in a double-blinded fashion.  Patients will be allowed to maintain their HCM-related background medications for the duration of the EXPLORER-HCM Phase 3 trial, including beta blockers or calcium channel blockers.  An independent data monitoring committee (IDMC) has been established to monitor safety throughout the study.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis ...

  • GlobeNewswire2 months ago

    MyoKardia Announces Pricing of Public Offering of Common Stock

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $49.00 per share, before underwriting discounts. MyoKardia anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and short-term and long-term investments, to fund research and development activities for its development programs, including, but not limited to, its planned Phase 3 EXPLORER-HCM clinical trial of mavacamten and its planned Phase 2 clinical trial of MYK-491, as well as its other ongoing and planned clinical trials for mavacamten and MYK-491, its ongoing preclinical, discovery and research programs and the expansion of its platform, and for working capital and other general corporate purposes.

  • GlobeNewswire2 months ago

    MyoKardia Announces Proposed Public Offering of Common Stock

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase an additional 562,500 shares of common stock at the public offering price, less the underwriting discount.

  • GlobeNewswire2 months ago

    MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

    Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO 2 and NYHA Classification Improvements. Expected to Initiate in Second Quarter ...

  • GlobeNewswire2 months ago

    MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

    SOUTH SAN FRANCISCO, Calif., May 10, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...

  • GlobeNewswire2 months ago

    MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

    SOUTH SAN FRANCISCO, Calif., May 10, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...

  • Associated Press2 months ago

    MyoKardia: 1Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 50 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    MyoKardia Reports First Quarter 2018 Financial Results

    Company to Host Conference Call and Webcast Today at 4:30 p.m. ET. SOUTH SAN FRANCISCO, Calif., May 08, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine ...

  • GlobeNewswire3 months ago

    MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018

    SOUTH SAN FRANCISCO, Calif., May 03, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...

  • Big Pharma's billion-dollar scramble to invest in start-ups to fuel innovation
    CNBC4 months ago

    Big Pharma's billion-dollar scramble to invest in start-ups to fuel innovation

    Big pharma is rushing to close its innovation gap by investing in start-ups that can help them develop breakthrough drugs.

  • Associated Press4 months ago

    MyoKardia reports 4Q loss

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 21 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...